TaraLLinMDMSCR

Oncology • Kansas City, KS

Hematologic Oncology

Director, Acute Leukemia Program Medical Director, Clinical Trials Office University of Kansas Cancer Center Kansas City, KS

Join to view full profile

Dr. Lin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lin's full profile

Already have an account?

Office
3901 Rainbow Blvd
Kansas City, KS 66160
Phone+1 913-588-8877

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2003 - 2006
University of MarylandResidency, Internal Medicine, 2000 - 2003
Virginia Commonwealth University School of MedicineClass of 2000

Certifications & Licensure

MO State Medical License 2022 - 2026
KS State Medical License 2011 - 2025
LA State Medical License 2008 - 2018
MD State Medical License 2003 - 2008

Clinical Trials

Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia Start of enrollment: 2016 Nov 01
Completed
Phase 1
Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2021 Aug 27
Terminated
Phase 1, Phase 2
Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS Start of enrollment: 2015 Oct 01
Unknown status
Phase 1, Phase 2
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 Start of enrollment: 2019 Nov 25
Recruiting
Phase 1
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Start of enrollment: 2016 Nov 01
Recruiting
Phase 1, Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML Start of enrollment: 2016 May 01
Recruiting
Phase 2
Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome Start of enrollment: 2020 Jun 08
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

Randomized Phase II Study to Assess the Role of Single-Agent Nivolumab to Maintain Remission in Acute Myeloid Leukemia.
Athalia Rachel Pyzer, Laura W Dillon, Elad Sharon, Theodore G Karrison, Yuanyuan Zha
Blood Advances. 2025-02-10
Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy.
Geoffrey L Uy, Vinod Pullarkat, Praneeth Baratam, Robert K Stuart, Roland B Walter
Blood Advances. 2024-12-24
North American Cancer Center Clinical Research Capacity and Benchmarking in the Postpandemic Era.
Margaret Kasner, Angela H Fritsche, Man Chong Leong, Kendra Cameron, Carrie B Lee
JCO Oncology Practice. 2024-12-01

Press Mentions

MyeloMATCH Plans to Bring Precision Treatments to U.S. Blood Cancer PatientsSeptember 24th, 2024